KCT0005323招募中未知
The effect of EVOlocumab and combination lipid-lowering agent on infarct size in patients with ST-segment Elevation Myocardial Infarction undergoing primary percutaneous coronary intervention; A prospective, randomized controlled trial (EVO-STEMI)
BUCHEON SEJONG HOSPITA0 个研究点目标入组 166 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 166
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 30(Year) 至 80(Year)（—）
- 性别
- All
入选标准
- •1) 30-80 years of age
- •2) >30 minutes in duration of typical chest pain
- •3) =1 mm of ST-segment elevation on = 2 contiguous leads
- •4) Onset of ischemic symptoms <12 hours ago
- •5) agree with study enrollment
排除标准
- •1) Prior myocardial infarction
- •2) Previous history of coronary artery bypass graft
- •3) Cardiogenic shock or cardiac arrest of more than 10 min
- •4) Acute left main coronary artery occlusion
- •5) Pregnancy or have a plan for pregnancy
- •6) Serum creatinine >2.5 mg/dL or hemodialysis is required
- •7) Expected survival < 1 year or poor compliance
- •8) Contraindication to cardiac MRI
- •9) previous administration of evolocumab within one month
- •10) body weight less than 40 kg
- •11) hypersensitivity or allergy to study drugs
- •12) active liver disease or high serum aminotransferase levels
- •13) genetic problems such as muscle disease, cyclosporin co-administration, galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
研究者
相似试验
已完成
不适用
Impact of lipid-lowering therapy with Evolocumab on coronary plaque regression in patients with coronary artery diseaseJPRN-UMIN000023448Chiba University Graduate School of Medicine3
进行中（未招募）
1 期
Does Evolocumab increase blood flow in coronary arteries?Coronary artery diseaseMedDRA version: 20.0 Level: PT Classification code 10005422 Term: Blood cholesterol System Organ Class: 10022891 - InvestigationsMedDRA version: 20.0 Level: LLT Classification code 10002434 Term: Angiogram coronary System Organ Class: 10022891 - InvestigationsEUCTR2018-002483-11-GBImperial College London120
已完成
4 期
The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular DiseaseAtherosclerotic Vascular DiseaseType2 DiabetesMicrovascular DysfunctionNCT03829046Robert Rosenson41
招募中
Unknown
Impact of Aggressive Lipid-Lowering Therapy with Evolocumab on Peripheral Atherosclerotic Plaque Assessed with NIRS-IVUS in Patients with Peripheral Artery DiseasePeripheral artery diseaseJPRN-UMIN000049231niversity of Fukui Division of Cardiovascular Medicine, Faculty of Medical Sciences30
尚未招募
Unknown
A comparative study of EVOlocumab and high-intensity statin for EARLY and intensive LDL-Cholesterol reduction in patients with acute coronary syndrome; Multi-center, prospective, randomized, double blinded, sham-procedure and placebo controlled trialKCT0009668BUCHEON SEJONG HOSPITA108